List of Excipients in Branded Drug KISQALI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	CELLULOSE, MICROCRYSTALLINE	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	CROSPOVIDONE	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	FERRIC OXIDE RED	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	FERROSOFERRIC OXIDE	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	HYDROXYPROPYL CELLULOSE	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	LECITHIN, SOYBEAN	2036-10-14
Novartis Pharmaceuticals Corporation	KISQALI	ribociclib	0078-0860	MAGNESIUM STEARATE	2036-10-14

Kisqali Excipient Strategy and Commercial Opportunities: Formulation, Generic Risk, and Lifecycle Analysis

Last updated: August 9, 2026

Kisqali (ribociclib succinate) is a once-daily, orally administered CDK4/6 inhibitor marketed by Novartis. Its commercial opportunity extends beyond the active ingredient. Excipient selection affects tablet manufacturability, dose flexibility, bioequivalence, supply continuity, patient adherence, and potential lifecycle products. The strongest opportunities are in generic-compatible formulation platforms, differentiated low-lactose or lactose-free products, pediatric or geriatric dosage forms, and manufacturing processes that improve dissolution and content uniformity.

What is Kisqali and how is it formulated?

Kisqali is approved for HR-positive, HER2-negative breast cancer in combination with an aromatase inhibitor or fulvestrant. It is also approved with an aromatase inhibitor for certain patients with early breast cancer at high risk of recurrence. The drug is supplied as film-coated tablets containing 200 mg of ribociclib as ribociclib succinate.

The approved metastatic breast cancer regimen generally uses 600 mg once daily for 21 consecutive days followed by seven days off treatment. Some patients receive 400 mg or 200 mg once daily because of toxicity management. This dose structure creates a commercial need for reliable 200 mg unit tablets and packaging that supports dose reductions without tablet splitting.

Reported inactive ingredients

The U.S. prescribing information identifies the following inactive ingredients for Kisqali tablets:

Excipient	Likely formulation function
Colloidal silicon dioxide	Glidant and flow aid
Crospovidone	Superdisintegrant
Hypromellose	Film-coating polymer
Lactose monohydrate	Diluent and compressibility aid
Magnesium stearate	Lubricant
Microcrystalline cellulose	Filler and compression aid
Povidone	Binder
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier
Iron oxide colorants	Tablet-color control

The precise quantitative composition is proprietary. FDA labeling confirms the qualitative excipient set but does not disclose the commercial manufacturing formula or process parameters. [1]

What excipient functions are most important for Kisqali tablets?

The core formulation must balance high-dose loading, tablet strength, rapid disintegration, chemical stability, and consistent dissolution. Ribociclib tablets are administered in a repeated 21-day cycle, so manufacturing variability can affect both exposure and dose-adjustment reliability.

Diluent and compression system

Lactose monohydrate and microcrystalline cellulose provide bulk and compressibility. Their combination is commercially practical for conventional immediate-release tablets, but it creates several formulation considerations:

• Lactose requires control of moisture, particle size, and supplier variability.
• Microcrystalline cellulose supports hardness and compactability but can affect disintegration at high compression force.
• Lactose-reducing or lactose-free alternatives may require reformulation of granulation, tablet weight, and dissolution behavior.
• Direct compression could reduce process steps, while wet granulation may improve content uniformity and tablet robustness.

A generic developer should treat the diluent system as a critical formulation variable rather than a simple substitution opportunity.

Binder and disintegrant system

Povidone supports granule or tablet cohesion. Crospovidone promotes rapid liquid uptake and tablet breakup. The ratio between binder and superdisintegrant can materially affect dissolution, especially after changes in compression force or lubricant level.

Over-lubrication with magnesium stearate can reduce wettability and slow dissolution. A commercial process should therefore control blending time and lubricant distribution. Crospovidone particle size and grade can also affect disintegration and dissolution performance.

Film-coating system

Hypromellose, talc, titanium dioxide, and iron oxide colorants provide the film coating. The coating protects the tablet, creates product identity, and supports visual inspection. For a generic product, the coating is a potential source of differentiation but also a source of avoidable regulatory complexity.

A coating strategy could target:

• Lower coating weight to reduce manufacturing cost.
• Titanium-dioxide-free color systems where market requirements justify the change.
• Improved moisture-barrier performance.
• Color matching that supports substitution without creating medication-error risk.
• Printing or packaging controls that preserve tablet identification during dose reduction.

Because the tablet is intended to be swallowed whole, coating performance is primarily relevant to stability, appearance, handling, and dissolution rather than taste masking.

What formulation patents and intellectual property protect Kisqali?

Kisqali is protected by a combination of active-ingredient, pharmaceutical-composition, solid-state, manufacturing, and method-of-use rights. The relevant intellectual-property categories are more important than any single excipient patent.

Active ingredient and composition claims

Ribociclib-related patents may cover substituted pyrimidine compounds, pharmaceutical salts, compositions, and therapeutic use. These claims can create barriers for generic products even when a manufacturer uses different excipients.

A generic developer must distinguish between:

1. Patents covering ribociclib or ribociclib succinate itself.
2. Patents covering particular crystalline or amorphous forms.
3. Patents covering tablet compositions or manufacturing processes.
4. Patents covering treatment regimens and patient populations.
5. Patents listed in the FDA Orange Book for the approved product.

The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity. [2] A current freedom-to-operate review must evaluate the Orange Book alongside USPTO records, international patent families, and active litigation dockets.

Method-of-use patents

Kisqali’s expanded early-breast-cancer indication increases the commercial value of method-of-use protection. Patents directed to HR-positive, HER2-negative disease, treatment sequencing, recurrence-risk populations, or combination therapy may affect a generic launch even after composition patents expire.

Skinny-label strategies may reduce infringement exposure where a generic omits patented indications from its labeling. They do not eliminate all litigation risk. Physicians may still prescribe the product for protected uses, and the commercial practicality of a carve-out depends on the remaining unpatented market.

Excipient and manufacturing protection

The individual excipients used in Kisqali are established pharmaceutical materials and are unlikely to provide meaningful standalone exclusivity. Protection is more likely to arise from:

• Specific excipient ratios.
• Granulation or blending conditions.
• Particle-size distributions.
• Dissolution profiles linked to a formulation.
• Moisture-control or coating processes.
• Stable solid forms or salt forms.
• Manufacturing methods that improve yield or reduce degradation.

These claims can raise development costs even when the generic formulation uses different inactive ingredients.

When does Kisqali lose exclusivity?

Kisqali’s regulatory exclusivity has largely matured, but patent timing remains the key launch variable. FDA approved Kisqali in July 2017 under the new drug application pathway. The original new chemical entity exclusivity period generally ran for five years, subject to any applicable pediatric extension. Later indication expansions do not reset NCE exclusivity. [1,3]

Exclusivity element	Kisqali relevance
FDA approval	July 2017
Original regulatory pathway	New drug application
NCE exclusivity	Generally expired in 2022
Early breast cancer expansion	FDA approval announced in 2024
Generic pathway	ANDA with paragraph IV or paragraph III certifications
Biosimilar pathway	Not applicable because ribociclib is a small molecule
Main remaining barrier	Listed and unlisted patent rights, plus market-access execution

The precise generic-entry date depends on the active patent estate, any patent-term extension, pediatric exclusivity, ANDA litigation, settlement terms, and the outcome of paragraph IV challenges. Patent expiration dates should be taken from the current Orange Book and underlying patent records rather than inferred from the 2017 approval date. [2]

What generic entry risks exist for Kisqali?

Kisqali has meaningful generic exposure because it is an oral small molecule with a conventional immediate-release tablet dosage form. The product does not require the biologic comparability package, complex device development, or cold-chain infrastructure associated with many biologics.

Likely generic development route

A conventional ANDA applicant would generally seek:

• Pharmaceutical equivalence to 200 mg ribociclib tablets.
• Bioequivalence under FDA requirements.
• Comparable dissolution across relevant media.
• Stability data under ICH conditions.
• A formulation that supports 200 mg, 400 mg, and 600 mg dosing through multiple tablets.
• Paragraph III certifications for unexpired patents or paragraph IV certifications where the applicant challenges patent validity, enforceability, or infringement.

The 200 mg unit strength simplifies dose construction but increases tablet-count exposure at lower and higher doses. Packaging, blister configuration, and labeling are important because patients commonly take three tablets per day during the 21-day treatment interval.

Commercial launch scenarios

Scenario	Commercial effect
First generic after patent expiry	Rapid price erosion and formulary substitution
Paragraph IV settlement with licensed launch	Controlled entry date and possible authorized generic
Multiple simultaneous ANDA approvals	Faster price compression
Limited first-wave competition	Higher generic margins and stronger wholesaler positioning
Indication carve-out	Partial market access, with reduced exposure to patented uses
Authorized generic launch	Lower net prices before broad generic entry

Novartis may preserve value through contracting, supply agreements, indication-specific positioning, or an authorized generic arrangement. The early breast cancer indication expands the addressable market and may increase the financial impact of any later generic entry.

What commercial opportunities exist for Kisqali excipient suppliers?

Excipient suppliers can capture value without owning the finished drug. The most attractive opportunities are tied to supply assurance, regulatory consistency, and reformulation support.

Supply-chain opportunities

A supplier can compete on:

• Pharmaceutical-grade lactose and microcrystalline cellulose with narrow particle-size specifications.
• Low-peroxide and low-moisture povidone.
• Consistent crospovidone grades for rapid disintegration.
• Magnesium stearate with controlled fatty-acid composition.
• Hypromellose and coating systems with reproducible viscosity and color.
• Dual sourcing and regional inventory for contract manufacturers.

For a high-value oncology product, supply interruption carries a disproportionate commercial cost. Suppliers that can provide validated alternate grades, change-control support, and regulatory documentation may obtain preferred status with generic manufacturers.

Reformulation opportunities

Potential differentiated products include:

1. Lactose-free tablets for patients with excipient intolerance or preference.
2. Smaller tablets with improved swallowability.
3. High-strength tablets that reduce tablet burden, subject to dosing and regulatory constraints.
4. Dispersible or oral-suspension formulations for patients unable to swallow tablets.
5. Pediatric formulations if a clinically justified pediatric indication emerges.
6. Packaging-integrated adherence systems aligned with the 21-days-on, seven-days-off cycle.

A modified-release product is less attractive because Kisqali already has once-daily administration and the approved product is immediate release. A new release profile would require substantial clinical and regulatory support.

How does Kisqali compare with other CDK4/6 inhibitors?

Kisqali competes with Ibrance (palbociclib) and Verzenio (abemaciclib). Excipient and dosage-form strategies differ across the class.

Product	Active ingredient	Dosing pattern	Dosage-form opportunity
Kisqali	Ribociclib	Once daily, 21 days on and seven days off	Adherence packaging, lactose-free tablet, dose-pack optimization
Ibrance	Palbociclib	Once daily, 21 days on and seven days off	Generic tablet or capsule competition, packaging differentiation
Verzenio	Abemaciclib	Continuous twice-daily or once-daily regimens depending on dose	Tablet-size reduction and adherence support

Kisqali’s once-daily dosing and expanding early-breast-cancer use support a strong commercial position. Its generic vulnerability is greater than that of complex biologic products, but formulation and patent barriers can delay practical market entry.

What is the FDA regulatory status of Kisqali?

FDA approved Kisqali for advanced or metastatic HR-positive, HER2-negative breast cancer in 2017 and expanded its use to certain early breast cancer patients in 2024. The product remains an approved prescription drug marketed by Novartis. [1,4]

For generic applicants, FDA review will focus on pharmaceutical equivalence, bioequivalence, manufacturing controls, impurity limits, dissolution, stability, and labeling. Excipients that differ from the reference product are permissible when supported by the applicable ANDA requirements and do not create safety, performance, or bioequivalence concerns.

How strong is the Kisqali formulation estate?

The formulation estate is moderately defensible at the individual-excipient level and potentially stronger at the process, solid-state, and use-claim levels. Lactose, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and hypromellose are widely used materials. A generic applicant can often avoid direct infringement by selecting alternative grades or excipient combinations.

The stronger barriers are likely to involve the active pharmaceutical ingredient, salt or crystal form, therapeutic indications, and manufacturing know-how. The practical strength of the estate depends on claim scope, expiration, prosecution history, Orange Book listings, and litigation outcomes.

What patent litigation and settlement issues affect generic entry?

A paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework. Litigation may result in:

• A 30-month FDA approval stay.
• Early settlement with a negotiated launch date.
• A license allowing entry before patent expiration.
• An authorized generic arrangement.
• A judgment invalidating or upholding asserted claims.
• A narrow label carve-out that limits commercial reach.

Publicly available information should be checked against current FDA Orange Book entries, ANDA litigation records, PACER filings, and USPTO patent-status data. Settlement agreements may allocate launch dates, supply rights, or restrictions by indication. [2,5]

Key Takeaways

• Kisqali uses a conventional film-coated immediate-release tablet with lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, colloidal silicon dioxide, and a hypromellose-based coating system.
• The main excipient value drivers are compression performance, dissolution control, moisture stability, coating consistency, and supply continuity.
• Kisqali is a small molecule, so biosimilar risk does not apply. Generic competition through the ANDA pathway is the relevant threat.
• NCE exclusivity has expired, but patent and litigation timing remain central to generic entry.
• The strongest commercial opportunities are lactose-free or alternative-diluent formulations, improved adherence packaging, pediatric or geriatric dosage forms, and validated excipient supply platforms.
• The early breast cancer indication increases the revenue exposure associated with future generic entry.
• Individual excipients provide limited exclusivity. Active-ingredient, solid-state, method-of-use, formulation-process, and manufacturing rights are more commercially important.

FAQs

Can a generic Kisqali use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and performance.

Is Kisqali suitable for a lactose-free reformulation?

Potentially. Replacing lactose would require optimization of tablet weight, compressibility, disintegration, dissolution, stability, and bioequivalence. The reformulation would have commercial value only if it produces a meaningful patient, manufacturing, or market-access benefit.

Does Kisqali have biosimilar competition?

No. Ribociclib is a chemically synthesized small molecule. Competition is expected through generic drug applications rather than biosimilar applications.

Can Kisqali be made as an oral liquid?

A liquid or dispersible product is technically possible, but it would require development of chemical stability, dose uniformity, palatability, preservative strategy, packaging, and clinical or bioequivalence support. Its strongest use case would be patients unable to swallow tablets.

Which excipient is most important for Kisqali dissolution?

Crospovidone, lubricant level, diluent selection, compression force, and tablet porosity collectively influence dissolution. No single excipient should be treated as the sole dissolution driver without process and formulation data.

References

1. U.S. Food and Drug Administration. (2024). Kisqali (ribociclib) prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Regulatory exclusivity and patent information for approved drug products. https://www.fda.gov

4. Novartis Pharmaceuticals Corporation. (2024). Novartis Kisqali reduces risk of recurrence in early breast cancer in landmark Phase III trial. Novartis investor and regulatory materials.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.